Early Intervention of Prodromal Schizophrenia Using an NMDA Enhancer
Status:
Recruiting
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Previous studies found that some NMDA-enhancing agents were able to improve clinical symptoms
of patients with schizophrenia. Whether treatment of an NMDA-enhancing agent can benefit the
treatment of prodromal schizophrenia deserves study.